{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:20:01Z","timestamp":1790695201792,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie\/Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie and the Ligue contre la cardiomyopathie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy associated with a high risk of ventricular arrhythmia (VA). Current guidelines recommend beta-blockers as first-line medical therapy and if ineffective, sotalol or amiodarone. We describe our experience, as a tertiary centre for ARVC, with the effectiveness and tolerance of flecainide in addition to beta-blockers to prevent VA in ARVC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We retrospectively included 100 consecutive ARVC patients who received flecainide with beta-blockers between May 1999 and November 2017. Treatment persistence and related side effects were assessed, as was VA-free survival on treatment, 24-h Holter monitoring and programmed ventricular stimulation (PVS) off- and on-treatment. Tolerance was good, with 10% flecainide discontinuations (lack of efficacy in six, atrial fibrillation in one, and side effects in three). No Brugada-induced electrocardiography pattern on flecainide or haemodynamic impairment was reported. Premature ventricular contraction burden at 24-h Holter monitoring was significantly decreased under treatment [median 415 (interquartile range, IQR 97\u2013730) vs. 2370 (1572\u20133400) at baseline, P &amp;lt; 0.0001, n = 46]. Among the 33 patients with PVS under treatment, PVS was positive in 40% on-treatment vs. 94% off-treatment (P &amp;lt; 0.001). During a median follow-up of 47 months (IQR 23\u201373), 22 patients presented sustained VA on treatment, corresponding to an event rate of 5% [95% confidence interval (CI) (0.6\u20139)] at 1 year and 25% [95% CI (14\u201335)] at 5 years under treatment. No patient died.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euab182","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T19:13:08Z","timestamp":1625512388000},"source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy"],"prefix":"10.1093","author":[{"given":"Thomas","family":"Rolland","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Badenco","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Maupain","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Duthoit","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Waintraub","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Laredo","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Himbert","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Frank","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Hidden-Lucet","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Gandjbakhch","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"APHP, Piti\u00e9-Salp\u00eatri\u00e9re University Hospital, Institute of Cardiology, Paris, France"},{"name":"Centre de R\u00e9f\u00e9rence des Maladies Cardiaques H\u00e9r\u00e9ditaires, Paris, France"},{"name":"Action Coeur Study Groupe, Paris, France"},{"name":"Institute of Cardiometabolism and Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"2021083012514126000_euab182-B1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacc.2018.05.065","article-title":"Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: JACC state-of-the-art review","volume":"72","author":"Gandjbakhch","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021083012514126000_euab182-B2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2261-13-52","article-title":"Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials","volume":"13","author":"Al-Gobari","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"2021083012514126000_euab182-B3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/CIRCEP.112.975441","article-title":"High prevalence of catecholamine-facilitated focal ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia\/cardiomyopathy","volume":"6","author":"Philips","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2021083012514126000_euab182-B4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jacc.2009.04.052","article-title":"Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy","volume":"54","author":"Marcus","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2021083012514126000_euab182-B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.CIR.86.1.29","article-title":"Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia","volume":"86","author":"Wichter","year":"1992","journal-title":"Circulation"},{"key":"2021083012514126000_euab182-B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00059-005-2677-6","article-title":"Arrhythmogenic right ventricular cardiomyopathy: antiarrhythmic drugs, catheter ablation, or ICD?","volume":"30","author":"Wichter","year":"2005","journal-title":"Herz"},{"key":"2021083012514126000_euab182-B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/eurheartj\/ehv162","article-title":"Treatment of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: an international task force consensus statement","volume":"27","author":"Corrado","year":"2015","journal-title":"Eur Heart J"},{"key":"2021083012514126000_euab182-B8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0735-1097(97)00190-3","article-title":"Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest","volume":"30","author":"Haverkamp","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2021083012514126000_euab182-B9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hrthm.2016.12.010","article-title":"Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"14","author":"Ermakov","year":"2017","journal-title":"Heart Rhythm"},{"key":"2021083012514126000_euab182-B10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/eurheartj\/ehq025","article-title":"Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed Modification of the Task Force Criteria","volume":"31","author":"Marcus","year":"2010","journal-title":"Eur Heart J"},{"key":"2021083012514126000_euab182-B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jacep.2018.04.017","article-title":"Risk stratification in arrhythmogenic right ventricular cardiomyopathy\/dysplasia without an implantable cardioverter-defibrillator","volume":"4","author":"Maupain","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"2021083012514126000_euab182-B12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9149(92)91392-H","article-title":"Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension","volume":"70","author":"Capucci","year":"1992","journal-title":"Am J Cardiol"},{"key":"2021083012514126000_euab182-B13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat Med"},{"key":"2021083012514126000_euab182-B14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass","volume":"48","author":"Hilliard","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"2021083012514126000_euab182-B15","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"57","author":"van der Werf","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2021083012514126000_euab182-B16","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.3390\/ijms20163986","article-title":"Calcium as a key player in arrhythmogenic cardiomyopathy: adhesion disorder or intracellular alteration?","volume":"19","author":"Moccia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2021083012514126000_euab182-B17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41467-017-00127-0","article-title":"Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm","volume":"8","author":"Cerrone","year":"2017","journal-title":"Nat Commun"},{"key":"2021083012514126000_euab182-B18","doi-asserted-by":"crossref","first-page":"41387","DOI":"10.1038\/srep41387","article-title":"Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: a systematic review and meta-analysis","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"2021083012514126000_euab182-B19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"2021083012514126000_euab182-B20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/CIRCULATIONAHA.113.003077","article-title":"Missense mutations in plakophilin-2 cause sodium current deficit and associate with a brugada syndrome phenotype","volume":"129","author":"Cerrone","year":"2014","journal-title":"Circulation"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euab182\/40081921\/euab182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euab182\/40081921\/euab182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T12:52:04Z","timestamp":1630327924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/advance-article\/doi\/10.1093\/europace\/euab182\/6359546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1093\/europace\/euab182","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"article-number":"euab182"}}